Skip to main content
main-content

Lung cancer

News and opinion

15-01-2019 | Non-small cell lung cancer | News

miRNA signature could supplement PD-L1 as NSCLC immunotherapy marker

Combining a plasma-based microRNA signature with tumoral tissue expression of programmed cell death ligand 1 could help identify advanced non-small-cell lung cancer patients who are unlikely to benefit from immune checkpoint inhibition, suggests an exploratory study.

Source:

Clin Cancer Res 2019; doi:10.1158/1078-0432.CCR-18-1981

11-01-2019 | Tyrosine kinase inhibitors | News

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

Source:

Cancer 2019; doi:10.1002/cncr.31917

10-01-2019 | Non-small cell lung cancer | News

Autoimmune antibodies predict clinical benefit, adverse events in NSCLC

The presence of some autoimmune antibodies prior to treatment with programmed cell death protein 1 inhibitors is associated with both clinical benefit and immune-related adverse events in patients with non-small-cell lung cancer, researchers report.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.5860

07-01-2019 | Mesothelioma | News

Anti-PD-L1 agent shows promise in malignant mesothelioma

The programmed cell death ligand 1 inhibitor avelumab has clinical activity and a manageable toxicity profile in patients with previously treated, unresectable malignant mesothelioma, according to phase Ib trial results.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.5428

04-01-2019 | FDA | News

approvalsWatch

Atezolizumab, larotrectinib approvals announced by FDA

More information on use of these agents here

21-12-2018 | Lung cancer | News

News in brief

Lung cancer ctDNA sequencing allows timely initiation of targeted therapy

Digital next-generation sequencing of circulating tumor DNA is a clinically useful option for advanced lung adenocarcinoma patients with insufficient tumor biopsy samples, say researchers.

21-12-2018 | Non-small cell lung cancer | News

Clinical course of EGFR-mutant NSCLC transforming to SCLC documented

Epidermal growth factor receptor-mutant non-small-cell lung cancer that transforms to small-cell lung cancer is characterized by a high rate of TP53 mutation and a lack of response to immunotherapy, among other features, show researchers.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.18.01585

14-12-2018 | Small-cell lung cancer | News

Veliparib shows efficacy in some patients with extensive-stage SCLC

Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.18.00264

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

03-12-2018 | FDA | Drug approval | News

approvalsWatch

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

26-11-2018 | Non-small cell lung cancer | News

Adjuvant erlotinib delays recurrence in stage IA–IIIA NSCLC

Adjuvant erlotinib significantly prolongs disease-free survival, compared with a historic benchmark, in patients with epidermal growth factor receptor-mutated stage IA–IIIA non-small-cell lung cancer, US research shows.

Source:

J Clin Oncol 2018; doi:10.1200/JCO. 18.00131

21-11-2018 | Checkpoint blockade | News

Specific cardiovascular toxicities associated with immune checkpoint inhibitor use

Patients treated with immune checkpoint inhibitors are at increased risk for cardiovascular immune-related adverse events including those associated with myocarditis, pericardial disease, and vasculitis, suggests an analysis of the WHO pharmacovigilance database.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30608-9

19-11-2018 | Checkpoint blockade | News

Clinically important safety differences found among immune checkpoint inhibitors

A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.

Source:

BMJ 2018; 363: K4266

13-11-2018 | Non-small cell lung cancer | News

Lorlatinib shows promising activity against ALK-positive advanced NSCLC

Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30649-1
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30789-7

05-11-2018 | Lung cancer | News

NCRI 2018 in brief

Impact of undertreatment on reduced survival in older lung cancer patients quantified

A modeling study presented at the 2018 NCRI Conference in Glasgow, UK, estimates that around 38% of the survival difference between older and younger patients with lung cancer may be due undertreatment in the older age group.

01-11-2018 | Immunotherapy | ESMO 2018 | News

News in brief

Anti-PD-1 immunotherapy feasible for patients with HIV and cancer

A database analysis reported at the ESMO 2018 Congress in Munich, Germany, points to the feasibility of using immune checkpoint inhibitors in people living with HIV who develop cancer.

01-11-2018 | Non-small cell lung cancer | ESMO 2018 | News

Neoadjuvant erlotinib evaluated for EGFR-mutated stage IIIA-N2 NSCLC

The CTONG-1103 EMERGING trial investigators believe that neoadjuvant treatment with epidermal growth factor receptor–tyrosine kinase inhibitors for stage IIIA-N2 non-small-cell lung cancer warrants further investigation.

Source:

ESMO 2018; Munich, Germany; 19–23 October

31-10-2018 | Non-small cell lung cancer | ESMO 2018 | News

ALESIA confirms first-line alectinib benefit in Asian advanced NSCLC patients

The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.

Source:

ESMO 2018; Munich, Germany; 19–23 October

22-10-2018 | Non-small cell lung cancer | ESMO 2018 | Video

Mechanisms of acquired resistance to osimertinib in AURA3

Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).

21-10-2018 | Non-small cell lung cancer | ESMO 2018 | News

Candidate mutations underlying acquired resistance to osimertinib mapped

Analyses of the FLAURA and AURA3 trials presented at the ESMO 2018 Congress in Munich, Germany, shed light on the genetic mechanisms of acquired resistance to the third generation EGFR–tyrosine kinase inhibitor osimertinib.

Source:

ESMO 2018; Munich, Germany; 19–23 October

image credits